Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jeffrey M. Clarke"'
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz
Publikováno v:
Current Oncology Reports. 23
Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur w
Autor:
Sipeng Shen, Carolyn Glass, Jeffrey M. Clarke, David C. Christiani, Qingyi Wei, Dongfang Tang, Sheng Luo, Hongliang Liu, Wen Gao, Li Su, Yu Chen Zhao
Publikováno v:
Int J Cancer
The ketone metabolic pathway is a principle procedure in physiological homeostasis and induces cancer cells to switch between glycolysis and oxidative phosphorylation as their main energy production. We conducted a two-phase analysis for associations
Autor:
Betty C. Tong, Gita Suneja, Jeffrey M. Clarke, Jordan A. Torok, Neal Ready, Corbin D. Jacobs, Xiaofei Wang, Junheng Gao, Chris R. Kelsey
Publikováno v:
Clin Lung Cancer
There is a paucity of data to guide management of patients with inoperable stage IIB (American Joint Committee on Cancer eighth edition) non–small-cell lung cancer. Practice patterns and comparative effectiveness analyses were performed for 10,081
Autor:
Andrew Craig MacKinnon, Kunle Odunsi, Lynn Dressler, Vincent Giamo, Mark Gardner, Matthew Labriola, Mark R Steciuk, Laura J. Tafe, Ben George, Jacob Hagen, Hongbin Chen, Jeffrey M. Conroy, Isabel Araujo-Fernandez, Konstantin H. Dragnev, Oliver A Binns, Wiam Bshara, Jeffrey M. Clarke, Tian Zhang, Edwin Yau, Mary Nesline, Deepa Kasuganti, Felicia L. Lenzo, Neel Shah, Matthew Zibelman, Sean T. Glenn, Blake Burgher, Marc S. Ernstoff, Jonathan Andreas, Rajbir Singh, Katherine G. Madden, Wang Yirong, Grace K. Dy, Pooja Ghatalia, Jonathan Thompson, Robin Jacob, Keisuke Shirai, Arun K Singavi, Daniele Marin, Antonios Papanicolau-Sengos, Sarabjot Pabla, Jason Zhu, Amy P. Early, Razelle Kurzrock, Carl Morrison, Shannon J. McCall, Lorenzo Galluzzi
Publikováno v:
Journal for immunotherapy of cancer, vol 7, iss 1
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b943366b5609140ecd0641fc7b25e61
https://escholarship.org/uc/item/5gr3z6s1
https://escholarship.org/uc/item/5gr3z6s1
Autor:
Aaron, Struck, Thomas, Howard, Elena G, Chiorean, Jeffrey M, Clarke, Robert, Riffenburgh, Higinia R, Cardenes
Publikováno v:
Journal of surgical oncology. 100(2)
Duodenal adenocarcinoma (DA) is rare, but potentially curable. Prospective data on treatment outcomes is scarce and large retrospective studies show conflicting results on the impact of radical resection, node-status, and adjuvant therapy.In the past